In a prestigious recognition of his outstanding contributions to the healthcare industry, Dr. Stephen Dilly, President and CEO of Codexis, Inc., has been awarded the highly esteemed 2023 Bloom Burton Award.
This honor acknowledges his exceptional leadership during his tenure as the head of Sierra Oncology, a Vancouver-based company, and his instrumental role in shepherding the company’s momelotinib through Phase 3 clinical development.
Dr. Dilly’s leadership at Sierra Oncology culminated in a significant milestone – the approval of momelotinib by the U.S. Food and Drug Administration on September 15, 2023. This remarkable achievement was not only a testament to his strategic vision but also a testament to the dedication and hard work of the entire Sierra Oncology team.
Upon receiving this prestigious award, Dr. Dilly expressed his gratitude and emphasized the importance of a strong, collaborative team in achieving success. He acknowledged the support and dedication of the individuals who played a pivotal role not only in Sierra Oncology but also in Aimmune Therapeutics.
Dr. Dilly’s leadership journey continues as he leads Codexis, where he is surrounded by a talented team dedicated to delivering exceptional enzymes for the advancement of human health. This recognition serves as a testament to his leadership, vision, and commitment to making a positive impact in the healthcare industry.
The Bloom Burton Award is an annual accolade presented to an individual who has made the most significant contribution to Canada’s innovative healthcare sector in the previous year. Nominees are drawn from the general public, and the winner and finalists are selected by an independent panel of judges comprised of global leaders in healthcare investment, entrepreneurship, and journalism. Dr. Stephen Dilly’s exceptional achievements and contributions have rightly earned him this distinguished award.
Codexis is at the forefront of enzyme engineering, harnessing its cutting-edge CodeEvolver® technology platform to discover, develop, and enhance novel, high-performance enzymes and other protein classes. These remarkable enzymes offer practical solutions to a wide range of challenges encountered in the manufacturing of small molecule pharmaceuticals and nucleic acid synthesis.
One of Codexis’ groundbreaking initiatives is the development of its proprietary ECO Synthesis™ platform, which holds the potential to revolutionize the production of RNAi therapeutics through an enzymatic approach.
Codexis’ enzymes are uniquely positioned to deliver tangible benefits, including increased yields, reduced energy consumption, minimized waste generation, enhanced manufacturing efficiency, and heightened sensitivity in genomic and diagnostic applications.
Codexis stands as a beacon of innovation in the field of enzyme engineering, and its dedication to pushing the boundaries of what enzymes can achieve is transforming industries and advancing the frontiers of science and technology. With a relentless commitment to excellence, Codexis continues to pave the way for groundbreaking advancements in healthcare, pharmaceuticals, and beyond.